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Abstract
The common non-steroidal anti-inflammatory drug ibuprofen has been associated with a reduced risk of some age-related
pathologies. However, a general pro-longevity role for ibuprofen and its mechanistic basis remains unclear. Here we show
that ibuprofen increased the lifespan of Saccharomyces cerevisiae, Caenorhabditis elegans and Drosophila melanogaster,
indicative of conserved eukaryotic longevity effects. Studies in yeast indicate that ibuprofen destabilizes the Tat2p
permease and inhibits tryptophan uptake. Loss of Tat2p increased replicative lifespan (RLS), but ibuprofen did not increase
RLS when Tat2p was stabilized or in an already long-lived strain background impaired for aromatic amino acid uptake.
Concomitant with lifespan extension, ibuprofen moderately reduced cell size at birth, leading to a delay in the G1 phase of
the cell cycle. Similar changes in cell cycle progression were evident in a large dataset of replicatively long-lived yeast
deletion strains. These results point to fundamental cell cycle signatures linked with longevity, implicate aromatic amino
acid import in aging and identify a largely safe drug that extends lifespan across different kingdoms of life.
Citation: He C, Tsuchiyama SK, Nguyen QT, Plyusnina EN, Terrill SR, et al. (2014) Enhanced Longevity by Ibuprofen, Conserved in Multiple Species, Occurs in Yeast
through Inhibition of Tryptophan Import. PLoS Genet 10(12): e1004860. doi:10.1371/journal.pgen.1004860
Editor: Stuart K. Kim, Stanford University Medical Center, United States of America
Received June 20, 2014; Accepted October 29, 2014; Published December 18, 2014
Copyright:  2014 He et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This work was supported by grants to MP (National Science Foundation: MCB-0818248; IIP-1265349) and to BKK (National Institutes of Health: R01-
AG043080; R01-AG025549). CH was supported by a postdoctoral fellowship from the Glenn Foundation for Medical Research. AAM was supported by grants from
the Presidium of RAS (12-P-4-1005), RFBR (14-04-01596), and the President of Russian Federation (MD-1090.2014.4). The open access publishing fees for this article
have been covered by the Texas A&M University Online Access to Knowledge (OAK) Fund, supported by the University Libraries and the Office of the Vice
President for Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: bkennedy@buckinstitute.org (BKK); polymenis@tamu.edu (MP)
Introduction
Levels of cellular and organismal dysfunction increase dramat-
ically with old age. Aging is the greatest risk factor for numerous
pathologies, including most forms of cancer, stroke, neurodegen-
erative disorders, heart disease and diabetes [1]. Hence, delaying
aging therapeutically promises immense benefits to human health
[2]. However, even with short-lived model organisms, the labor
and time associated with unbiased screens for compounds that
extend lifespan is a major obstacle [3,4]. To overcome this
drawback, many studies focus on compounds that target pathways
already implicated in aging, such as TOR signaling [5,6], AMP
kinase [7], and Sirtuins [8,9]. Alternatively, phenotypes associated
with aging are used as a proxy in screens for potential anti-aging
therapeutics [3]. These phenotypes usually include resistance to
various types of stress and mitochondrial degeneration, as well as
maintenance of proteostasis and genomic stability [10]. The
ultimate goal of all these approaches is to identify drugs that will
delay the onset of age-related dysfunction and/or provide novel
therapeutics to the diseases of aging [2].
Studies of replicative and chronological lifespan in the budding
yeast Saccharomyces cerevisiae have been driving forces in the
identification of conserved genetic pathways that extend lifespan
[11,12]. In this organism, individual cells can be tracked from
birth to death [13], with the number of divisions a cell can
undergo defining its replicative lifespan (RLS) [14]. The pathways
controlling yeast RLS and C. elegans lifespan exhibit significant
overlap [15]. Hence, aging studies in yeast and other model
systems represent invaluable platforms for the discovery of
therapeutics that affect aging and a mechanistic dissection of their
mode of action.
However, translating leads from aging screens in yeast and
other model organisms to drugs that are efficacious and safe in
humans represents a significant hurdle [2]. Alternatively, emphasis
could be placed on relatively safe compounds that are already used
in humans for some indication. One could then ask whether such
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compounds could extend the lifespan of model organisms. If
successful, these drugs would represent excellent candidates for
testing in humans for outcomes on healthspan parameters and
biomarkers of longevity. They would also serve as invaluable tools
to probe conserved longevity pathways, expanding and deepening
our understanding of the basic biology of aging.
Here we show that ibuprofen, a common and relatively safe
non-steroidal anti-inflammatory drug, extends the lifespan of S.
cerevisiae, C. elegans and D. melanogaster. We find that ibuprofen
extends the replicative lifespan of yeast cells by destabilizing the
high-affinity tryptophan transporter. We also show that ibuprofen
causes a small size at birth and a moderate delay in initiation of
cell division. Mirroring the effects of ibuprofen, we found that
most long-lived yeast mutants were also moderately delayed in
initiation of cell division, primarily due to a smaller size at birth.
These results point to fundamental cellular properties associated
with longevity, and identify a relatively safe drug that alters these
properties and extends the lifespan of different species.
Results
Ibuprofen extends the lifespan of S. cerevisiae, C. elegans
and D. melanogaster
We decided to focus on ibuprofen for three reasons: First, it is a
relatively safe over-the-counter medication. Second, ibuprofen
may be associated with reduced risk of some age-related
pathologies. Third, ibuprofen has not been reported to target
any of the known aging pathways (e.g., the TOR or Sirtuin
pathways), offering the possibility of novel insights into aging
mechanisms. Ibuprofen was invented over 50 years ago. It is the
prototypical 2-aryl-propionic acid NSAID. Relative to other
NSAIDs, ibuprofen is arguably one of the safest [16–19], and is
in the World Health Organization’s ‘‘model list of essential
medicines’’ (18th edition, 2013). As other NSAIDs, ibuprofen has
analgesic and anti-pyretic indications. However, these indications
stem from ibuprofen’s well-established role as a cyclooxygenase
inhibitor, interfering with prostaglandin biosynthesis [20]. With
regard to age-related pathologies, long-term ibuprofen use
reduced the risk of Alzheimer [21] and Parkinson [22,23] diseases
by more than 30%. However, it is unlikely that these beneficial
outcomes were solely due to ibuprofen’s anti-inflammatory roles
because they were not necessarily shared by other NSAIDs. For
example, among the NSAIDs examined, ibuprofen showed the
most profound reduction in Alzheimer risk (40%), while others,
such as celecoxib, had no effect [21]. Similarly, ibuprofen alone,
but not other NSAIDs tested, reduced the risk of Parkinson disease
[22]. To our knowledge, despite the vast number of studies dealing
with ibuprofen, there are no direct measurements of ibuprofen’s
effects on the lifespan of organisms.
Consequently, we decided to measure the effects of ibuprofen
on yeast replicative lifespan. Added at 0.2 mM, we found that
ibuprofen significantly extended the RLS of the standard BY4742
strain background (<17%, p,0.0001, see Fig. 1A). To test if
ibuprofen extends the lifespan of organisms other than yeast, we
turned to C. elegans for three reasons: First, C. elegans is a well-
established metazoan aging model, allowing us to gauge the ability
of ibuprofen to extend the lifespan of organisms from different
kingdoms of life [24]. Second, as in yeast, in C. elegans we could
probe ibuprofen’s effects independently of its role as a cycloox-
ygenase inhibitor because this organism lacks cyclooxygenase
enzymes [25], which are targeted by ibuprofen in mammals [20].
Third, in C. elegans ibuprofen has been shown to suppress a
phenotype associated with aging, inhibiting the deposition of
amyloid b peptide, a marker for Alzheimer disease [26]. We found
that animals exposed continuously to varying doses of ibuprofen
(0.010–0.4 mM) from hatching until death had a longer lifespan
(S1 Table). Note that we used UV-killed bacteria in these
experiments, so it is unlikely that these effects are due to indirect
effects through the action of ibuprofen on bacterial metabolism
(see Materials and Methods). The concentration of ibuprofen at
which the lifespan extension was maximal was 0.1 mM (Fig. 1B
and S1 Table).
To further test the conservation of the pro-longevity effects of
ibuprofen, we asked if the drug could extend the lifespan of D.
melanogaster, another aging model system. Although the COX
gene is absent in Drosophila, cyclooxygenase-like activity and
inflammatory responses are thought to be present [27–29]. We
found that ibuprofen (at 0.5 mM) extended the mean and the
maximum lifespan of female flies (Fig. 1D and S2 Table). In males,
although mean lifespan may also be extended, this was accom-
panied by a reduction of the maximum lifespan at all doses tested
(Fig. 1C and S2 Table). The reasons for the sex-dependent
differences in the longevity effects of ibuprofen are not clear.
Although the effect in flies is influenced by the sex of the animal, it
is nonetheless remarkable that ibuprofen promotes longevity in
organisms as divergent as yeast, worms and flies.
Overall, these results suggest that ibuprofen extends lifespan
across different kingdoms of life. At least in the case of yeast and
worms, the pro-longevity function of ibuprofen is through non-
cyclooxygenase-related activity.
Ibuprofen extends RLS by moderately inhibiting import
of aromatic amino acids
To understand how ibuprofen might extend lifespan, we
focused on the yeast system for the remainder of this report. A
previous study interrogated systematically single gene deletions
that were sensitive to ibuprofen [30]. Seven out of the eight genes
encoding enzymes for de novo synthesis of tryptophan were
among the 28 gene deletions that sensitized cells specifically to
ibuprofen [30]. To account for these observations, we hypothe-
sized that ibuprofen may interfere with import of aromatic amino
acids, including tryptophan. In this scenario, mutants lacking the
ability to make tryptophan would rely exclusively on mechanisms
responsible for importing tryptophan. Such mutants would be
sensitive to any drugs that may impair tryptophan import, perhaps
explaining their sensitivity to ibuprofen. To test this model, we
then measured directly import of tryptophan in cells treated with
ibuprofen. Indeed, ibuprofen inhibited the import of [14C]-
Author Summary
Aging is the greatest risk factor for many diseases, which
together account for the majority of global deaths and
healthcare costs. Here we show that the common drug
ibuprofen increases the lifespan of yeast, worms and flies,
indicative of conserved longevity effects. In budding yeast,
an excellent model of cellular longevity mechanisms,
ibuprofen’s pro-longevity action is independent of its
known anti-inflammatory role. We show that the critical
function of ibuprofen in longevity is to inhibit the uptake
of aromatic amino acids, by destabilizing the high-affinity
tryptophan permease. We further show that ibuprofen
alters cell cycle progression. Mirroring the effects of
ibuprofen, we found that most yeast long-lived mutants
were also similarly affected in cell cycle progression. These
findings identify a safe drug that extends the lifespan of
divergent organisms and reveal fundamental cellular
properties associated with longevity.
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tryptophan (Fig. 2A). Impaired import of amino acids, including
tryptophan, could alter their intracellular pools. Consequently, we
measured intracellular levels of amino acids after cells were
exposed for 1 hr to 0.2 mM ibuprofen (Fig. 2B), the same dose
that extended RLS (see Fig. 1A). We found that the levels of
several amino acids were moderately affected by ibuprofen, either
increasing, or decreasing, compared to untreated cells (Fig. 2B and
S3 Table). Ibuprofen lowered the levels of all aromatic amino
acids (Fig. 2B and S3 Table). Overall, these results support the
notion that exposing cells to a concentration of ibuprofen that
extends RLS inhibits import of aromatic amino acids and lowers
their intracellular levels.
Tat2p and Tat1p are the high- and low-affinity tryptophan
permeases, respectively [31,32]. Tat1p is also the high affinity
tyrosine permease [31], and may also be involved in the transport
of valine and threonine [33]. In addition to tryptophan, Tat2p can
transport tyrosine, phenylalanine and, to a lesser extent, alanine
and glycine [33]. In agreement with earlier reports [31],
tryptophan uptake was moderately inhibited in cells lacking
Tat1p, more so in cells lacking Tat2p, and completely blocked in
cells lacking both Tat1p and Tat2p (S1 Figure).
To test whether inhibition of aromatic amino acid import is
sufficient to extend lifespan, we measured the RLS of tat1D and
tat2D cells (Fig. 2C). Loss of Tat2p extended RLS significantly
(Fig. 2C). We next asked if the ability of ibuprofen to extend RLS
depends on aromatic amino acid transport. We found that RLS
extension by ibuprofen was attenuated in tat2D cells and
eliminated in cells lacking both Tat1p and Tat2p (Fig. 2D), which
cannot import any tryptophan (S1 Figure and [31]). Cyclooxy-
genase enzymes are not present in yeast [25]. Therefore, ibuprofen
must affect yeast cells via unknown off-target mechanisms. Among
possible novel mechanisms, our results point to regulation of
tryptophan import through Tat2p as a primary conduit by which
ibuprofen extends yeast lifespan.
Ibuprofen extends RLS by destabilizing Tat2p
One of the earliest discovered outputs of the TOR pathway in
yeast involves control of tryptophan import and regulation of
Tat2p stability [34,35]. When the Tor1p kinase is active, its
downstream effector kinase Npr1p is hyperphosphorylated and
inactive. However, inhibiting TOR with rapamycin leads to the
dephosphorylation and activation of the Npr1 kinase, which
Fig. 1. Ibuprofen extends the lifespan of S. cerevisiae, C. elegans and D. melanogaster. A, Ibuprofen extends yeast RLS. Survival curves for
MATa (BY4742) cells treated with ibuprofen at 0.2 mM (shown in red), compared to experiment-matched untreated cells (shown in black). Mean
lifespans are shown in parentheses, along with the number of cells assayed. B, Ibuprofen extends the lifespan of C. elegans. Survival curves for wild
type (N2 strain) animals, treated with ibuprofen at 0.1 mM compared to experiment-matched untreated cells. Mean lifespans are shown in
parentheses, along with the number of animals assayed. The data shown are from S1 Table. C, D, Ibuprofen extends the lifespan of female D.
melanogaster. Survival curves for wild type male (C) and female (D) animals, treated with ibuprofen at 0.05 mM compared to experiment-matched
untreated cells. Mean lifespans are shown in parentheses, along with the number of animals assayed. The data shown are from S2 Table.
doi:10.1371/journal.pgen.1004860.g001
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triggers the degradation of Tat2p [36,37]. Inhibition of TOR
activity is a well-characterized, conserved mechanism that delays
aging [5,6]. Furthermore, tryptophan auxotrophs are more
sensitive to rapamycin [34] and to ibuprofen [30]. Interestingly,
we found that ibuprofen re-sensitized to rapamycin otherwise
rapamycin-resistant mutants in the TOR pathway, such as TOR1-
1, TOR2-1 and npr1D, suggesting interactions between ibuprofen
and the TOR pathway (S2 Figure). For the above reasons, we
examined whether ibuprofen functions through the TOR pathway
to inhibit the import of aromatic amino acids and extend RLS.
Since the TOR pathway controls Tat2p stability and sorting, we
examined Tat2p levels in cells treated with ibuprofen. For protein
surveillance experiments, we used strains carrying a single allele of
the gene of interest, encoding a C-terminal TAP-tagged version of
the otherwise wild type ORF, expressed from its native
chromosomal location [38]. As reported previously [36], inhibition
of TOR by rapamycin reduced Tat2p levels (Fig. 3A). Within 30–
60 min after exposure to 0.2 mM ibuprofen, steady-state levels of
Tat2p-TAP were reduced to a degree similar to that upon
exposure to rapamycin (Fig. 3A). Next, we asked if the reduction
in steady-state Tat2p-TAP levels were attributable to destabiliza-
tion of the protein. We monitored Tat2p-TAP levels after the cells
were exposed to cycloheximide, to block new protein synthesis.
From these experiments, we estimated that Tat2p-TAP had a half-
life of 28 min (Fig. 3B, top panels), consistent with data from a
genome-wide study that evaluated with the same approach the
stability of TAP-tagged proteins [39]. However, upon addition of
0.2 mM ibuprofen, the half-life of Tat2p-TAP was reduced to
about 10 min (Fig. 3B, bottom panels). Next, we measured by
qPCR steady-state mRNA levels of TAT2 and TAT1 after
exposure to ibuprofen or rapamycin. We did not observe a
significant difference in the steady-state levels of these mRNAs
upon exposure to ibuprofen (Fig. 3C, top). We conclude that in
cells treated with ibuprofen the drop in Tat2p levels is likely the
result of destabilization of this permease.
Since both rapamycin and ibuprofen destabilize Tat2p, we next
asked if ibuprofen affects other TOR-mediated responses. We
evaluated known molecular outputs of the TOR pathway after
treatment with ibuprofen, in comparison to cells treated with
rapamycin. First, we looked at transcriptional outputs (Fig. 3C).
Fig. 2. Ibuprofen inhibits tryptophan import, reduces intracellular tryptophan levels and does not extend RLS in the absence of
tryptophan permeases. A, Uptake of [14C]-tryptophan (y axis) is shown at the indicated time points (x axis) after the cells were exposed to, and
allowed to internalize, [14C]-tryptophan, together with ibuprofen, rapamycin, or no treatment, as indicated. The average of 2 independent
experiments is shown, while the error bars indicate the variability between the two experiments. B, Intracellular amino acid pools. The percentage
difference in the amino acid levels between the ibuprofen-treated (0.2 mM) and untreated (0 mM) samples is shown on the x-axis. The average of six
independent experiments (each analyzed in quadruplicate) and the associate standard deviation is shown. All the obtained values from these amino
acid analyses are shown in S3 Table. C, Survival curves for MATa tat2D cells (BY4742 strain background) treated with ibuprofen at 0.2 mM (shown in
purple), compared to experiment-matched untreated cells (shown in red). For comparison, wild type (WT) cells (BY4742 background) were also
included in this experiment and they were either untreated (shown in black) or treated (shown in blue) with ibuprofen. Mean lifespans are shown in
parentheses, along with the number of cells assayed. D, Survival curves for wild type and tat1D, tat2D cells (BY4741 strain background) treated with
ibuprofen at 0.2 mM compared to experiment-matched untreated cells. Mean lifespans are shown in parentheses, along with the number of cells
assayed.
doi:10.1371/journal.pgen.1004860.g002
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Inhibition of TOR by rapamycin is known to trigger expression of
mRNAs under the control of the Gln3p and Gcn4p transcription
factors [35]. Gcn4p is activated downstream of the Gcn2p kinase.
There are also some mRNAs whose transcription is activated in a
manner that is Gcn2p-dependent, but Gcn4p-independent
[35,40]. We confirmed all these responses to rapamycin (Fig. 3C).
However, exposure to the ibuprofen dose (0.2 mM) that extends
RLS did not elicit any of the above TOR-dependent gene
expression changes (Fig. 3C). Since rapamycin addition mimics
amino acid starvation, triggering increased translation of GCN4
[41,42], we also asked if translation of GCN4 is affected by
ibuprofen. For these experiments, we used cells carrying a reporter
plasmid with GCN4 upstream regulatory sequences known to
mediate translational control of b-galactosidase expression [43].
Fig. 3. Ibuprofen destabilizes Tat2p without triggering other TOR pathway outputs. A, Steady-state Tat2p-TAP levels are reduced upon
ibuprofen treatment. Exponentially proliferating cells expressing from its chromosomal location TAP-tagged Tat2p were exposed to ibuprofen or
rapamycin at the indicated concentration and for the times shown. Tat2p levels were evaluated by SDS-PAGE and immunoblotting. From the same
samples, steady-state levels of untagged Cdc28p are shown for comparison. B, Ibuprofen destabilizes Tat2p-TAP. The experiment was performed as
in A, except that the cells were treated with cycloheximide at time 0. Tat2p-TAP band densities were quantified with Image J software. These values
were then normalized for loading and fitted on an exponential decay function to obtain the half-life values shown on the right of each blot. C,
Ibuprofen does not trigger gene expression of downstream effectors of the TOR pathway. Left, we examined three sets of targets of the TOR pathway,
whose expression is known to be affected by rapamycin. Right, expression of the targets genes shown was evaluated by qPCR (see Materials and
Methods) from exponentially growing cells after addition of ibuprofen (at 0.2 mM) or rapamycin (at 50 ng/ml) at the indicated times. The targets
were grouped based on the diagram shown on the left. We also included TAT1 and TAT2 expression in this experiment. The average values from at
least three experiments in each case were log2-transformed and displayed on the heatmap shown using the open-source pheatmap package for the
R language. D, Ibuprofen does not trigger Gln3p dephosphorylation. Cells expressing TAP-tagged variants of two downstream effector of TOR, Npr1p
and Gln3p, were treated with ibuprofen or rapamycin for 60 min, at the same concentrations as in A. Npr1p-TAP and Gln3p-TAP levels and mobility,
evaluated by immunobloting. E, Ibuprofen does not extend the RLS of a strain that carries the stable 2HA-TAT2-5KR allele. Survival curves of the
strains shown treated with ibuprofen at 0.2 mM compared to experiment-matched untreated cells. For comparison, wild type cells carrying a similarly
tagged wild type TAT2 allele (2HA-TAT2) were also included in this experiment and they were either untreated (shown in black) or treated (shown in
red) with ibuprofen. Mean lifespans are shown in parentheses, along with the number of cells assayed.
doi:10.1371/journal.pgen.1004860.g003
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Although rapamycin increased b-galactosidase expression signifi-
cantly, the increase in b-galactosidase expression upon ibuprofen
addition was minimal (S3 Figure). These results indicate that
ibuprofen at doses that increase RLS does not lead to a general
amino acid limitation, consistent with our measurements of
intracellular amino acid pools (Fig. 2B and S3 Table).
We also measured different readouts of TOR-dependent
signaling in cells treated with ibuprofen at the dose that extends
RLS. A downstream effector of TOR is Npr1p, which is
dephosphorylated upon rapamycin addition [37,44]. Whereas
Npr1p-TAP appeared to migrate as a single species in rapamycin-
treated cells, it migrated as a doublet on SDS-PAGE in both
untreated and ibuprofen-treated cells (Fig. 3D). These findings are
consistent with TOR-dependent regulation of Npr1p [37], and
indicate that ibuprofen likely does not regulate Tat2p stability in
an Npr1p-dependent manner. We then examined another TOR
effector, the transcription factor Gln3p. Rapamycin triggers the
dephosphorylation of Gln3p [35], leading to a fast-migrating
species of Gln3p on SDS-PAGE [44,45]. Such a mobility shift was
very pronounced in cells treated with rapamycin but not in cells
treated with ibuprofen (Fig. 3D).
Next, we asked if destabilization of Tat2p is required for
ibuprofen’s ability to extend RLS. Degradation of Tat2p is
mediated by ubiquitination at N-terminal sites [36]. TAT2 alleles
encoding LysRArg substitutions at five N-terminal Lys residues
yield stable Tat2p variants [36]. In contrast to the extended RLS
of cells lacking Tat2p (Fig. 2C), cells expressing stabilized Tat2p-
5KR from the endogenous chromosomal location had reduced
RLS (Fig. 3E). Furthermore, ibuprofen did not extend the RLS of
cells expressing stabilized Tat2p-5KR (Fig. 3E). These results
suggest that destabilization of Tat2p is required for lifespan
extension by ibuprofen.
All the results described above indicate that although ibuprofen
destabilizes Tat2p, a known target of TOR, it does so without
significantly altering additional outputs of the TOR pathway.
Consequently, we next tested if ibuprofen extends RLS in the
context of TOR pathway mutants. Even though tor1D mutants
are long-lived [46], their RLS were increased further by ibuprofen
(Fig. 4). Ibuprofen also extended the RLS of npr1D, gln3D and
gcn4D cells, demonstrating that the corresponding gene products
are not required for its longevity-promoting effects (Fig. 4). Taken
together, these results suggest that the mechanism of RLS
extension we described for ibuprofen converges on the stability
of the Tat2p permease, which is also targeted by the TOR
pathway (Fig. 4E).
Ibuprofen treatment reduces cell size at birth and delays
the G1 phase of the cell cycle
Since preservation of a proliferative state is at the core of cellular
replicative lifespan, we decided to examine if exposure to
ibuprofen alters cell cycle kinetics. We used centrifugal elutriation
to obtain highly synchronous, unbudded, early G1 cell popula-
tions. We scored these cultures over time microscopically and with
a channelyzer, a particle counter that directly measures the
volume of cells. Note that in yeast initiation of DNA replication is
coupled to the formation of a bud [47]. Thus, one can monitor the
timing of initiation of division by phase microscopy. We calculated
the specific rate of size increase (which we call here ‘‘growth rate’’)
and critical size (the size at which half of the cells budded). We
then incorporated measurements of birth size, as we described
previously [48,49]. Knowing how small the cells are when they are
born, how big they have to get before they can divide, and how
fast they grow from their birth size to their critical size, determines
the absolute length of the G1 phase (Fig. 5A). With this
methodology, we examined in synchronous cultures G1 progres-
sion upon treatment with varying doses of ibuprofen (Fig. 5B and
S5 Figure). At lower doses, ibuprofen caused a dose-dependent
delay in G1 progression, mostly due to reduction in birth size
(Fig. 5 and S4 Figure). Ibuprofen also significantly compromised
growth rate at 0.4 mM or higher (Fig. 5C and S5 Figure). At even
higher doses, ibuprofen was toxic to yeast cells in this medium (not
shown). These results suggest that at the dose that ibuprofen
extends RLS, it also reduces cell size at birth and moderately
delays the G1 phase of the cell cycle.
Correlation of cell cycle parameters with RLS
We next asked whether the cell cycle alterations caused by
ibuprofen reflect more general links between cell cycle progression
and RLS. To answer this question, we first queried systematic
genome-wide datasets that report on these processes. Soon after
systematic panels of yeast deletion mutants were generated, with
each strain lacking a nonessential gene, they were assayed for their
competitive fitness [50], and for the mean cell size of asynchro-
nously dividing cell populations [51]. Recently, we also measured
by flow cytometry the DNA content of these mutants [48] and
calculated the birth size of the newborn daughter cells [49].
Together these studies provide phenotypes that are associated with
cell cycle progression (i.e., fitness, mean cell size, DNA content, and
birth size) for 3,979 single-gene deletion mutants. We have also
initiated a systematic measurement of the RLS of all these mutants
[46], but this effort is still ongoing. Nonetheless, in the Saccharo-
myces Genome Database (http://www.yeastgenome.org/), 137
deletion mutants in the same background have already been studied
and classified as having increased RLS, based on published data
from our group and others (see S1 Dataset, sheet ‘‘variables’’, for a
list of these ORFs and the corresponding variables). Collectively,
these datasets permit a much broader evaluation of possible links
between cell cycle progression and RLS.
We compared the cell cycle related phenotypes of the 137 long-
lived (LL) mutants with those of the remaining 3,842 not long-
lived (NLL) strains (S1 Dataset). We found that there was not a
highly significant difference in the mean cell size of the two groups
(S6 Figure and S1 Dataset). However, there were small but
significant differences in the birth size of newborn cells (S1
Dataset, based on both the parametric Student’s t test and the
non-parametric Mann-Whitney test). Overall, it appears that LL
mutants have a smaller birth size and reduced fitness, which likely
accounts for the moderate increase in the relative duration of the
G1 phase (S1 Dataset and S6 Figure). To better visualize these
differences, we plotted in a density scatter plot the birth size values
against the corresponding fitness for each mutant, for the LL and
NLL groups (Fig. 6). From these data, we conclude that although
LL mutants have a slightly smaller birth size and reduced fitness,
these relationships are constrained and not proportional. Com-
pared to NLL mutants, LL mutants were neither the smallest, nor
the least fit. To evaluate the extent that each of the above cell cycle
parameters could serve as predictors for long RLS, we also
performed binary logistic regression analysis (see S1 Dataset, sheet
‘‘Statistics’’). In the context of all the variables we analyzed, the
best predictor for long RLS was daughter birth size (p = 0.000613),
followed by fitness (p = 0.026).
The phenotypes we examined above were from cells dividing
asynchronously. Next, we evaluated synchronous cell populations,
to measure parameters that determine the absolute length of the
G1 phase of the cell cycle and the timing of initiation of a new
round of cell division. For this analysis, we compared a group of 14
LL strains to 13 NLL strains (see S4 Table). The mutants we chose
lack ORFs that function in diverse cellular processes, including
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metabolism, protein synthesis, growth signaling or transcription
(see S4 Table). From these experiments with synchronous cultures,
we conclude the following: Most LL mutants had a smaller birth
size (p = 0.026, based on a Mann-Whitney test), but they appear to
occupy a ‘‘sweet-spot’’ since strains with much reduced birth size
were not long-lived (Fig. 7A and S4 Table). However, at least for
the LL mutants we examined here, the size at which they initiated
division was normal (Fig. 7C and S4 Table). Many LL mutants
also had a reduced growth rate (Fig. 7B and S4 Table) but this
difference was not statistically significant (Mann-Whitney test).
Overall, these observations support our conclusion from the
genome wide datasets of parameters from asynchronous cultures
that smaller daughter birth size is a phenotype associated with
increased RLS (Fig. 6 and S1 Dataset). Furthermore, the fact that
critical size is not significantly altered in the long-lived mutants we
evaluated probably explains why the mean cell size of asynchro-
nous cultures is not a good predictor of long RLS.
Next, we asked about the efficiency of size control mechanisms
in the LL mutants. Plotting the logarithm of birth size against the
relative growth in the G1 phase of the cell cycle is a measure of the
efficiency of cell size control mechanisms [52,53]. In such plots, a
slope of zero indicates no size control. From single-cell analysis,
wild type budding yeast daughter cells display a negative slope of
0.7 [52,53]. We applied this methodology to all the synchronous
daughter cell populations of the LL strains shown in S4 Table and
also obtained a slope of 20.7 (Fig. 7D). We conclude that the LL
mutants we analyzed displayed cell size control that appeared to
be as efficient as that of the wild type strain (Fig. 7D). In the
Discussion, we comment on the implications of all these data, in
the context of recent models of cellular aging.
To follow our other findings, we also interrogated possible
connections among tryptophan levels, birth size, Tat2p stability
and replicative lifespan. We found that although the effects of
exogenous tryptophan on cell size were minimal (S7A Figure),
Fig. 4. Ibuprofen extends RLS of TOR pathway mutants. Ibuprofen extends the RLS of npr1D (A), tor1D (B), gln3D (C) and gcn4D (D) cells.
Survival curves of the strains shown (BY4742 background) treated with ibuprofen at 0.2 mM compared to experiment-matched untreated cells. Mean
lifespans are shown in parentheses, along with the number of cells assayed. E, Model of the mechanism of function of ibuprofen, acting
antagonistically but at least in part independently of the TOR pathway to destabilize Tat2p and inhibit tryptophan import in the cells.
doi:10.1371/journal.pgen.1004860.g004
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exogenous tryptophan suppressed ibuprofen’s pro-longevity effects
(S7B Figure). Furthermore, steady-state levels of epitope-tagged
Tat2p-TAP were not reduced in the hxk2D and rpl20bD mutants
with small birth size and increased RLS, and appeared instead to
be increased by <2 fold (S8 Figure). We also noted that there was
no disproportionate decrease in tryptophan levels in hxk2D and
sch9D mutants (S5 Table), which have a small birth size, and they
are long-lived (S4 Table). Instead, these mutants have lower levels
(<20%–60%) of nearly all amino acids, including tryptophan (S5
Table), resembling growth-limited cells in that regard [54].
However, stabilization of Tat2p increased birth size (Fig. 8A, B)
and suppressed the long lifespan of mutants with small birth size
(Fig. 8C, D). Taken together, these results suggest that a link
between small birth size and tryptophan levels is not straightfor-
ward. Replicative longevity in yeast is not always accompanied
with a small birth size, lower Tat2p abundance and lower
tryptophan levels. Nonetheless, stabilization of Tat2p both
increases the size of cells at birth, and attenuates the pro-longevity
effects upon loss of Hxk2p or Rpl20Bp.
Lastly, we asked whether interfering with the expression of
aromatic amino acid transporters could increase the lifespan of
animals. To this end, we tested whether using RNAi to suppress
expression of either one of two putative orthologs of Tat2p could
extend the lifespan of C. elegans, resembling the long lifespan of
yeast tat2D mutants. These worm orthologs are encoded by genes
C50D2.2 and F23F1.6, and the corresponding gene products are
24%, and 20%, identical to Tat2p, respectively. We found that
suppressing expression of C50D2.2 significantly increased both the
mean and the maximal lifespan of the RNAi-treated animals
(mean lifespan increased <15%, p,0.0001), compared to the
control animals (S9A Figure). Animals treated with RNAi against
F23F1.6 also lived longer, albeit the effect was less pronounced
(mean lifespan increased <5%, p= 0.0006, see S9B Figure). These
results suggest that targeting amino acid transport mechanisms
may have general pro-longevity effects.
Discussion
We will first consider the implications of our findings connecting
ibuprofen with tryptophan import and lifespan. We will also
discuss our results in the context of previous models linking cell
cycle progression with RLS.
Ibuprofen: A safe NSAID as a longevity therapeutic?
Although ibuprofen had not been tested for its effects on lifespan,
other common NSAIDs have been examined. Aspirin slightly
extended the lifespan of genetically heterogeneous male mice [54].
In the same study, a nitrosylated flurbiprofen analog had no effect
on the lifespan of mice [54]. Even against cyclooxygenases, NSAIDs
often display different modes of inhibition and specificity against
Fig. 5. Ibuprofen at low doses moderately delays G1, primarily through a reduction in birth size. A, Schematic of the variables that
determine the length of the G1 phase. B, The birth size of BY4743 cells exposed at different doses of ibuprofen was measured from three
independent experiments in each case, similar to the ones shown in S4 Figure. Asterisks indicate statistically significant differences compared to the
untreated samples (p,0.05, from Student’s t tests). C, The specific rate of cell size increase constant k (in h21) was measured from the elutriation
experiments shown in S5 Figure, assuming exponential growth. D, The critical cell size of the indicated strains (shown in fl), was measured from the
same elutriation experiments shown in C and S5 Figure.
doi:10.1371/journal.pgen.1004860.g005
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specific isoforms. For example, flurbiprofen causes irreversible
inhibition of cyclooxygenase activity while ibuprofen does not [20].
Another NSAID that has been reported to extend the lifespan of C.
elegans is celecoxib [55]. Similar to our results with ibuprofen,
celecoxib extended lifespan when added from hatching until death
[55]. We also noted that the effective pro-longevity concentrations
of ibuprofen were much lower in flies than in worms or yeast
(0.5 mM vs. 100–200 mM, respectively; see Fig. 1). The reason for
this difference is unclear at present. In healthy humans who took a
600 mg ibuprofen dose up to four times daily, the peak plasma
concentration was around 50 mg/ml, corresponding to 240 mM
[56]. In another study, a single 400 mg dose of ibuprofen results in a
plasma concentration of 8.4 mg/ml, or 40 mM [57]. Therefore, the
levels of ibuprofen that extend the lifespan of worms and yeast are in
the range of ibuprofen levels reached in people taking the drug at
typical doses. Overall, our results add to the growing role of
NSAIDs, and ibuprofen in particular. These compounds are
relatively safe therapeutics that may combat age-related pathologies
and extend the lifespan of divergent organisms, from yeast to
invertebrates and possibly mammals.
Aromatic amino acid uptake: At the nexus of aging
mechanisms?
We discovered that ibuprofen inhibits tryptophan import, cells
lacking the high affinity tryptophan transporter are long-lived, and
ibuprofen’s longevity effects depend on its ability to destabilize the
high affinity tryptophan transporter (Figs. 2, 3). How important is
tryptophan uptake in meeting the needs of cells for this amino
acid? Metazoans cannot make tryptophan and rely exclusively on
tryptophan uptake. Plants and microbes, including yeast, can
synthesize tryptophan through the shikimate and chorismate
pathways [58]. However, tryptophan is by far the costliest amino
acid to synthesize, consuming 78 mol of ATP for 1 mol of
tryptophan [58]. Hence, given a choice, it is likely that tryptophan
uptake will be preferable to synthesis, even in tryptophan
prototrophs. Consistent with a role for tryptophan uptake in
aging, low tryptophan diets extend the lifespan of rodents [59].
Perhaps in line with our finding that worms with suppressed
expression of the yeast tryptophan permease orthologs live longer
(S9 Figure), tryptophan analogs that may inhibit the tryptophan
transport system have also been reported to increase the lifespan of
flies [60]. Conversely, an increase in degradation of tryptophan
through the kynuverine pathway has been associated with
accelerated aging in animals (reviewed in [61]). Tryptophan’s
roles are not limited to protein synthesis. For example, in animals,
kynuverine metabolites serve as immune and neuronal modulators
[61,62] and affect cell viability in tissue culture [63]. However, it is
not clear if tryptophan degradation and its involvement in the
above pathways are a cause or consequence of aging.
Our results expand the role of aromatic amino acids in aging.
We demonstrate that interfering with aromatic amino acid uptake,
genetically or pharmacologically, can extend lifespan. Further-
more, to our knowledge, the extended lifespan of tat2D cells
(Fig. 2) is the first report of an amino-acid permease deletion that
extends RLS in yeast. Perhaps this is a reflection of the incomplete
systematic evaluation of the RLS of permease mutants. Alterna-
tively, it may be due to the low abundance of tryptophan in the
cells, coupled to the energetic cost of synthesizing tryptophan.
Tryptophan levels are 5–10 times lower than the levels of the next
low-abundance amino acids (tyrosine and methionine, see S3
Fig. 6. LL mutant birth size and fitness are more constrained than those of NLL mutants. A, The birth size values (y axis) from all 3,842 NLL
mutants from S1 Dataset were plotted against their corresponding fitness values (x axis). Because many data points were overlapping, they were
binned using the hexbin function of the R software package. The displayed colors represent the number of strains within each bin, as indicated by
the color key to the right. B, The birth size values (y axis) from all 137 LL mutants from S1 Dataset were plotted against their corresponding fitness
values (x axis), as in A. The number of strains in each bin (counts) are shown on the right.
doi:10.1371/journal.pgen.1004860.g006
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Table). Finally, we would like to note that when ibuprofen was
added at the dose that extended RLS, the drop in tryptophan
levels was 15–20% (Fig. 2B and S3 Table). Hence, the cells were
not severely limited for tryptophan, or any other amino acid
(Fig. 2B and S3 Table), consistent with the lack of significant
GCN4 de-repression (S3 Figure). As we comment later, perhaps
this is yet another manifestation of hormesis, underpinning
ibuprofen’s effects in RLS.
Our results strongly suggest not only that ibuprofen destabilizes
the Tat2p permease (Fig. 3), but also that this is the critical function
of ibuprofen in mediating RLS extension since stabilization of
Tat2p neutralized the ability of ibuprofen to extend lifespan
(Fig. 3E). Stabilization of Tat2p also suppressed replicative lifespan
extension by loss of Hxk2p or Rpl20Bp (Fig. 8). The TOR pathway
is known to control the stability of Tat2p. A few years after the
discovery of the TOR genes in yeast [64], it was reported that
increased levels of TAT2 conferred resistance to the macrolide
FK506 [31,34]. Then, TOR activity was shown to inhibit turnover
of Tat2p, through Npr1p, a downstream effector kinase of TOR
[36,37]. Interestingly, however, loss of Npr1p does not stabilize
Tat2p, presumably because in the absence of Npr1p other kinases
substitute for Npr1p’s role [37]. In any case, in light of all this
information, it seemed plausible that ibuprofen increased RLS
through the TOR pathway. Indeed, ibuprofen conferred rapamycin
sensitivity to TOR gain-of-function mutants or cells lacking Npr1p
(S2 Figure). Such strains are normally resistant to rapamycin and
have increased Tat2p activity. We noted however that at the dose
that extended RLS, ibuprofen did not elicit molecular responses
consistent with TOR pathway inhibition (Fig. 3 and S3 Figure).
Furthermore, ibuprofen extended the RLS of both tor1D and
npr1D strains (Fig. 4), suggesting that it acts through a mechanism
that is at least partially distinct from reduced TOR signaling. It is
Fig. 7. G1 phase cell cycle parameters of LL and NLL strains. A, The birth size values (y axis) of the 14 LL and 13 NLL strains shown in S4 Table.
The filled black squares correspond to the values of the wild type control. The data from S4 Table were used to generate the graphs shown. B, The
specific rate of cell size increase (k, shown on the y axis) for the LL and NLL strains shown in S4 Table was calculated from synchronous, elutriated
cultures (see Materials and Methods). C, The critical size (y axis) of the LL and NLL strains shown in S4 Table was calculated from the same
experiments shown in B. D, LL mutants have efficient cell size control mechanisms. On the x axis is the logarithm of the normalized birth size values
of the LL mutants shown in S4 Table, plotted against their relative growth in size during the G1 phase of each strain (kTG1, y axis). The dashed line is a
linear fit obtained with the regression function of Microsoft Excel. The filled square is the wild type strain.
doi:10.1371/journal.pgen.1004860.g007
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possible that ibuprofen, through its destabilization of Tat2p and
inhibition of aromatic amino acid import, may further sensitize the
TOR pathway and exacerbate the longevity effects of TOR
pathway inhibition. Alternatively, ibuprofen may be acting in
parallel with the TOR pathway, to destabilize Tat2p, inhibit import
of aromatic amino acids, and extend RLS (Fig. 4E).
Cell cycle parameters and RLS: Hypertrophy or
antagonistic pleiotropy and hormesis?
As we detail next, our results argue against the hypertrophy
model of cellular aging. Before initiating a new round of cell
division, newborn daughter cells reach a critical size threshold.
Critical size is characteristic of the yeast strain and medium used.
Yeast mother cells also increase in size with every successive
division [65,66]. The hypertrophy model of aging proposed that
mother cells reach their replicative potential once they attain a
fixed maximal size, beyond which they cannot divide any more
[67,68]. This terminal and very large cell size may represent the
point at which cells have become so large that they cannot sustain
functions necessary for cell division, perhaps due to a very low
surface to volume ratio or for other reasons.
The hypertrophy model makes a clear prediction: For small cells,
it would take extra divisions to reach the terminal size, resulting in
longer RLS. Conversely, large cells will reach the terminal size after
fewer divisions, having a shorter RLS. Furthermore, changes in
RLS and cell size ought to be proportional. Specifically, it was
proposed that RLS is simply a quotient of the difference between
maximal and critical size values, and the increase in cell size per cell
division [67]. The hypertrophy model received a significant boost
from a recent report of changes in RLS that were indeed strongly
proportional to observed changes in size [69]. For example, a plot of
cell diameter at birth against RLS displayed a linear fit with a
coefficient of determination (R2) equal to 0.96 [69]. However, it was
pointed out that the above conclusions supporting a role for
hypertrophy in RLS were drawn from a small sample of mutants
(,15), of which no more than a handful were long-lived [70,71].
Short RLS can be due to many causes, with a significant portion
unlinked to the mechanistic events driving RLS [70,72]. We based
our conclusions on genome-wide datasets, parsed in two groups:
mutants with a longer lifespan against all the rest (S1 Dataset). We
found that the mean cell size of the two groups was similar (S1
Dataset and S6 Figure). This finding argues against a key prediction
of the hypertrophy model: LL mutants would have a small overall
cell size, which would in turn enable these cells to divide more times
until they reach the terminal size.
Yang et al also reported that the birth size of long-lived cells was
significantly and proportionally smaller than that of short-lived
cells [69]. Here, we also identified significant differences in birth
size between LL and NLL mutants, but these differences were
slight and they were not linearly proportional (S1 Dataset, S4
Table and Figs. 6,7). There are at least two reasons that may
account for these discrepancies: First, the sample sizes were vastly
different. Second, birth size was measured with different method-
ologies. Yang et al used photomicroscopy after micromanipulation
to measure cell diameters and then extrapolate to calculate the
birth size of those cells [69]. Instead, we relied on channelyzer
measurements, which report directly on volume, to obtain the size
of the smallest cells in dividing populations [49].
Fig. 8. Stabilization of Tat2p increases birth size and suppresses replicative lifespan extension in hxk2D and rpl20bD cells. A and B,
The cell size of the indicated haploid cell populations cultured in YPD (2% Dextrose) medium was measured using a channelyzer. Cell numbers are
plotted on the y axis and the x axis indicates size (in fL). C and D, Experiment-matched survival curves of the same strains shown in A and B. Mean
lifespans are shown in parentheses, along with the number of cells assayed.
doi:10.1371/journal.pgen.1004860.g008
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Longer RLS has been associated with reduced fitness [73] and
slower growth rate [69]. We also noticed that LL mutants have
reduced fitness (S1 Dataset and Fig. 6) and growth rate (Fig. 7 and
S4 Table). However, these differences were again modest and
constrained. The majority of the smallest and/or slowest growing
mutants were not long-lived (Fig. 6, and as an example see sfp1D
cells, S4 Table). We would also like to note that none of the 14 LL
mutants we analyzed with detailed synchronous cell cycle profiles
had significantly altered critical size (Fig. 7 and S4 Table). Based
on our data, it seems that LL mutants are born smaller and/or
grow slightly slower, but they reach a normal critical size before
initiating division. This is consistent with the observation that LL
and NLL mutants have similar mean size (S1 Dataset and S6
Figure). In fact, their size control appears intact and indistin-
guishable from wild type cells (Fig. 7D). Again, these observations
do not support the hypertrophy model.
The cell cycle patterns we described above argue that in most
cases long lifespan is associated with a moderate delay in cell cycle
progression early in life. This delay arises from a small birth size
and/or slower growth rate. As a result of these changes, LL
mutants have a G1 delay (S4 Table and S6 Figure). As was noted
previously, these observations are perhaps in line with the
antagonistic pleiotropy model [73]. In that scenario, mutations
that increase lifespan have opposite effects at different ages. A
small delay in cell cycle progression would have adverse effects in
young cells, decreasing their rates of division, but be beneficial in
older cells, enabling them to divide more times. It is also possible
that our results can be explained from the viewpoint of hormesis.
In hormetic situations, a treatment at low intensity or dose can be
beneficial, but at higher levels, the same treatment is harmful.
Hormetic responses to various types of stress are often associated
with lifespan extension [74]. Perhaps a moderate delay in G1
progression produces such beneficial effects in lifespan. At the
same time, it is not difficult to see why a more severe delay would
be detrimental. Hormetic considerations may explain why the cell
cycle differences we observed in LL mutants are moderate and
constrained, but not severe and proportional. This is illustrated by
the effects of ibuprofen: At low doses, ibuprofen causes a moderate
cell cycle delay, mimicking the profile of LL mutants (Fig. 5), and
extends lifespan (Fig. 1A). At higher doses, however, ibuprofen
delays cell proliferation more severely (Fig. 5). Regardless of the
models invoked, our data suggest that using cell cycle parameters
may be a promising and readily scalable approach to identify
interventions that extend RLS.
In conclusion, the results we report reveal unexpected cellular
properties associated with longevity and demonstrate that novel
functions of existing safe therapeutics can extend the longevity of
organisms from different kingdoms of life.
Methods
Strains and media
The strains we used are shown in S6 Table. Single gene deletion
mutants in the BY4741, BY4742, or BY4743 strains were
generated by the Yeast Deletion Project [50]. Double mutants
(e.g., strain CHY01) were constructed from crosses of the
corresponding single mutants, each in the background of opposing
mating types (BY4741 and BY4742), followed by tetrad dissection,
growth on selective media lacking lysine and methionine, and
genotyping by PCR.
The 2HA-TAT2 and 2HA-TAT2-5KR plasmids pAS55 and
pTB355, respectively, were gifts from Dr. Michael Hall [36]. To
generate strains carrying these alleles integrated in the chromo-
some, we performed the following: First, with one-step PCR
replacement [75], in strain BY4742 we replaced the TAT2 allele
with URA3, yielding a tat2D::URA strain (CHY02). Then, we
PCR-amplified the TAT2 ORF and flanking sequences from
plasmids pAS55 and pTB355, using primers that correspond to
upstream (Forward primer: 59- CCTTCTGAGTGACGCT-
TAAACCATCTGCAAGTCTCTTCCGCGGTGATGACGGT-
GAAAACC-39) and downstream (Reverse primer: 59- GACGC-
GAATTGTTTCACACGGTAGGATAAGAGAAATTGCGGA-
CGTTGTAAAACGACGGCC-39) flanking sequences. These
PCR products were then used to transform strain CHY02,
counter-selecting for the loss of the URA3 marker on plates
containing 5-Fluoroorotic Acid (5-FOA). The resulting transfor-
mants, CHY03 and CHY04, were genotyped by PCR to confirm
the presence of the 2HA-TAT2 and 2HA-TAT2-5KR alleles,
respectively, expressed from the endogenous TAT2 chromosomal
location. Note that the epitope tag did not alter the lifespan-related
function of Tat2p, because the 2HA-TAT2 strain had the same
RLS as the untagged but otherwise identical strain and its lifespan
was further extended by ibuprofen (Fig. 3E). With one-step PCR
replacement [75], in strain CHY04 (carrying the 2HA-TAT2-5KR
allele), we replaced the HXK2, or RPL20B, ORFs with URA3,
yielding strains CHY05, or CHY06, respectively. Similarly, using
strain 202233243 (carrying the TAT2-TAP allele) we generated
strains CHY07, CHY08, CHY09, lacking HXK2, RPL20B, or
SCH9, respectively.
Unless indicated otherwise, the medium we used in most
experiments, including cell cycle and RLS measurements, was
YPD (1% w/v yeast extract, 2%
w/v peptone, 2%
w/v dextrose).
We used the ibuprofen sodium salt (Sigma, Cat#: I1892) dissolved
in water to a 0.1 M stock solution, from which it was added to
autoclaved media as indicated in each case. Rapamycin (Sigma,
Cat#: R0395) was dissolved in ethanol to a 1 mg/ml stock, before
it was added to autoclaved media as indicated.
Cell cycle and RLS measurements
We have described in detail elsewhere the methodology for
elutriation experiments [48], birth size measurements [49] and
RLS assays [13]. The smoothened cell size histograms we show are
the splines of the corresponding raw data, generated with the R
software package ‘‘lattice’’. All RLS experiments were carried out
on standard YPD plates.
Tryptophan uptake assays
Cells from an early logarithmic culture in YPD medium were
divided in three. Drugs were added as indicated and the cultures
were incubated at 30uC for another 3 hrs. The three culture
fractions were treated as indicated (mock, 0.2 mM ibuprofen or
50 ng/ml rapamycin), and they were incubated for an additional
3 h at 30uC. Cultures were harvested by centrifugation and
washed twice in 10 mM sodium citrate, pH 5.5. The cell pellets
were resuspended in ice-cold uptake buffer (10 mM sodium citrate
(pH 5.5); 20 mM (NH4)2SO4; 2% glucose). The cell densities were
measured and normalized to 56107 cells/ml. While samples were
on ice, they were treated again as before (mock, ibuprofen at
0.2 mM, or rapamycin at 50 ng/ml). We then added radiolabelled
tryptophan solution (L-Tryptophan, [side chain-3-14C], 40–60
mCi/mmol, Moravek Biochemicals, Cat#: MC402). The cell
cultures were then incubated at 30uC for the times shown. At the
indicated time points, 0.1 ml aliquots were transferred to
microcentrifuge tubes containing 1 ml ice-cold uptake solution
to stop the uptake. The samples were centrifuged for 10 sec and
the cell pellets were washed three times (centrifuging for 10 sec in
between) with ice-cold uptake buffer. Finally, the cell pellets were
resuspended in 0.1 ml of uptake buffer and transferred to a vial
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containing 5 ml of scintillation mixture. The retained radioactivity
was then quantified by liquid scintillation using a Beckman
LS6500 Multipurpose Scintillation Counter.
Amino acid analysis
Cells were grown in rich YPD medium until they reached a
density of 1–56106 cells/ml. For drug treatment, the culture was
then divided in half and one part was treated with ibuprofen at
0.2 mM for 1 hr. After quenching with sodium azide (at 0.1%)
and cycloheximide (at 50 mg/ml), the cells were collected by
centrifugation and washed with water (1:20 volume, compared to
the original culture volume). The cells were collected again by a
brief spin (10 sec in a microfuge), and resuspended in 1:100
volume of water (compared to the original culture volume). Then,
the cell suspension was boiled for 5 min and centrifuged to collect
the supernatant, representing the metabolite extract. This extract
was then analyzed by standard PTH-derivatization and HPLC
analysis [76] at the Texas A&M University Protein Chemistry
Facility, to quantify the nmoles of each amino acid present in the
extract. These values were normalized for the starting cell density
and reported in S3 Table.
Immunoblotting
Protein extracts for immunoblots were made with the NaOH
extraction method [77]. The extracts were run on 4–12% gradient
SDS-PAGE gels. For detection of proteins of interest on
immunoblots we used a rabbit polyclonal anti-Cdc28 antibody
(SantaCruz, Cat#: sc28550) at a 1:500 dilution to detect Cdc28p,
a mouse monoclonal anti-PSTAIR antibody (Abcam, Cat#:
ab10345) at a 1:1000 dilution to detect Cdk, and the peroxidase-
anti-peroxidase (PAP) soluble complex (Sigma, Cat#: P1291) at a
1:1000 dilution to detect TAP-tagged proteins. Conjugated anti-
rabbit and anti-mouse secondary antibodies and chemilumines-
cence reagents were from Thermo Scientific, and used at the
dilutions recommended by the manufacturer.
Quantitative real-time PCR analysis
Cells were grown to early logarithmic phase in YPD medium
and treated with 0.2 mM ibuprofen or 50 ng/ml rapamycin for
0 min, 30 min, 60 min and 90 min, as indicated. Cells were
harvested and cell extracts were prepared using the glass bead lysis
method [75]. Total RNA was purified using the QIAGEN RNeasy
kit (Cat#: 74106) according to the manufacturer’s instructions.
1 mg RNA was reverse-transcribed using Bio-Rad’s iScript cDNA
synthesis kit (Cat#: 170-8890) containing oligo (dT) and random
hexamer primers. Lysate preparation, RNA purification and
reverse transcription were performed on multiple biological
samples in parallel. cDNA products were amplified with a Roche
LightCycler 480 using SYBRGreen I Master (Roche, Cat#:
04887352001) for detection according to manufacturer’s recom-
mendations. Primer sequences are listed in S7 Table. cDNA of
0 min treatment was used as standard for normalization.
b-galactosidase assays
The p180 reporter plasmid driving expression of b-galactosidase
was a gift from Dr. Alan Hinnebusch [43]. The plasmid was
transformed into BY4741 cells, and transformants were selected on
plates lacking uracil. Overnight cultures were diluted 1:100 in
synthetic complete medium lacking uracil. After incubation for 3 h
at 30uC, cell cultures were treated as indicated (mock, 0.2 mM
ibuprofen or 50 ng/ml rapamycin) and incubated for an additional
3-4 h at 30uC. We examined three independent cultures for each
treatment. Cells were harvested and cell extracts were prepared in Z
buffer (60 mM Na2HPO4.7H2O, 40 mM NaH2PO4.H2O, 10 mM
KCl, 1 mM MgSO4.7H2O, 50 mM b-mercaptoethanol) with glass
bead lysis. Protein concentrations were measured using Bradford
assay. Cell extracts were diluted in Z buffer after normalizing for the
same amount of protein. We then added 0.1 ml of cell extract into
96-well plates. To each well, we then added 20 ml of o-nitrophenyl-
b-D-galactopyranoside (ONPG, Sigma Cat#: 73660) solution
(4 mg/ml in Z buffer). Plates were incubated at 30uC for 40–
60 min until the color of the samples became pale yellow. OD450 nm
for each sample was measured using a SpectraMax 190 Absorbance
Microplate Reader.
C. elegans lifespans
All the experiments were done as described elsewhere [78].
From the single-cell egg stage, lifespans were monitored on plates
seeded with UV-killed bacteria (strain OP-50). Other than scoring
times, during which the animals were moved to room tempera-
ture, at all stages of these experiments the animals were kept at
20uC. RNA interference (RNAi) was delivered to worms as
described previously [79]. RNAi feeding bacteria were kind gifts
from Dr. Gordon Lithgow. Control animals were fed bacteria
carrying an empty vector (strain pAD12). Lifespan experiments
were performed in the second generation of animals grown on
RNAi bacteria.
D. melanogaster lifespans
Wild-type strain Canton-S were obtained from the Bloomington
Drosophila Stock Center (Indiana University, Bloomington, Indiana,
USA) and used in lifespan experiments. Flies were kept under
standard conditions, at 25uC, in a 12:12 hour light-dark regime, on
an agar/semolina/sugar/yeast medium [80]. 25 pairs of parents with
synchronized 24 h egg laying, were used to obtain the experimental
flies. The flies were extracted from vials immediately after imago
eclosion. 150–200 flies were collected (approximately 30 adult flies
per 50 ml vial) for each experimental variant. Males and non-virgin
females were kept separately. Flies were put in vials with medium
contained ibuprofen (Sigma Cat#: I110) at concentration of 0.3, 0.5
and 1 mM, and transferred to a fresh medium with ibuprofen twice
weekly. Dead flies were scored daily during Drosophila lifetime.
The data was used to plot survival curves and to calculate the
mean, median, minimum and maximum lifespan and the age of
90% mortality calculated with the open source R software
package. In order to estimate the significant statistical differences
between experimental and control groups, log-rank tests were
used. The significance of differences in maximum lifespan was
evaluated using the Wang-Allison test. Following the Wang-Allison
test, each animal in each experiment was categorized into one of
two groups: either lifespan above the 90th percentile or lifespan
below the 90th percentile. A two by two contingency table was
used to record data. An ordinary x2-test was used for independent
testing of two groups [81].
Supporting Information
S1 Figure Tryptophan uptake is inhibited in cells lacking Tat1p
and Tat2p. Uptake of [14C]-tryptophan (y axis) is shown at the
indicated time points (x axis) after the indicated strains were
exposed to, and allowed to internalize, [14C]-tryptophan.
(JPG)
S2 Figure Cells relying on tryptophan uptake are sensitive to
ibuprofen. Strains that are tryptophan auxotrophs (trp1D in the
BY4743 background and all strains in the Jk9-3d background, see
S6 Table) were sensitive to growth on solid medium containing
ibuprofen (compare the 1st and 2nd plates). Strains carrying
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dominant gain-of-function TOR1 or TOR2 alleles, or lacking
Npr1p are resistant to rapamycin (see [37] and this figure top,
compare the 1st and 4th plates). Interestingly, ibuprofen re-
sensitized these strains to rapamycin (bottom, 2nd plate). Therefore,
when cells rely on tryptophan uptake (e.g., in Trp auxotrophs, or
when TOR is inhibited, which through Npr1p affects Tat2p) they
are sensitive to ibuprofen. Adding additional exogenous trypto-
phan suppressed partially, albeit not completely, these effects of
ibuprofen. All strains were spotted at 5-fold serial dilutions on
YPD plates with the indicated chemicals, from the same starting
cell densities. The plates were incubated at 30uC, for 3 days and
they were photographed at the same time. Ibuprofen was added at
0.2 mM; Trp at 100 mg/ml; and Rapamycin at 50 ng/ml.
(JPG)
S3 Figure Ibuprofen does not relieve translational repression of
GCN4 expression. Absorbance associated with b-galactosidase
expression (y axis) for wild type cells carrying the p180 lacZ
reporter plasmid and treated as indicated (x axis).
(JPG)
S4 Figure Ibuprofen reduces the mean and birth cell size. The
cell size of exponentially proliferating cell populations (BY4743),
cultured in YPD (2% Dextrose) medium, and treated with the
indicated dose of ibuprofen was measured using a channelyzer.
Cell numbers are plotted on the y axis and the x axis indicates size
(in fL).
(JPG)
S5 Figure Determining the length of G1 in cells treated with
ibuprofen. A, Graphs from which we determined the specific rate
of cell size increase constant k, shown in Fig. 5C. We plotted the
natural log of the cells size (y axis), against time (shown in hours, x
axis). Measurements were from synchronous BY4743 cultures, in
rich (YPD-2% Dextrose) medium. After each elutriation, the
elutriated culture was split in four fractions. Ibuprofen was then
added to each fraction, to the final concentration shown in each
case. B, Graphs of the fraction of budded cells (y axis) as a function
of cell size (in fl, x axis), from the same elutriation experiments.
The data points used to determine the critical size for division we
show in Fig. 5D were from the linear portion of each experiment,
when the percentage of budded cells began to increase.
(JPG)
S6 Figure Kernel density plots of mean size and G1 DNA
content of LL vs. NLL mutants. A, The G1 DNA content in LL vs.
NLL mutants was plotted as a density plot using the open source R
software package, to better visualize the distribution of this
variable in the two groups of mutants. B, The mean cell size of LL
vs. NLL mutants was plotted as a density plot using the open
source R software package, as in A.
(JPG)
S7 Figure Exogenous tryptophan does not affect cell size, but it
suppresses replicative lifespan extension by ibuprofen. A, The cell
size of haploid cell populations (BY4741 background) cultured in
YPD (2% Dextrose) medium at the indicated tryptophan
concentrations was measured using a channelyzer. Cell numbers
are plotted on the y axis and the x axis indicates size (in fL). B, The
replicative lifespan extension (in percentage) of cells treated with
0.2 mM ibuprofen compared to their untreated counterparts
(BY4742 background) is shown at the indicated concentrations of
Trp, Phe or Tyr added in the medium (YPD, with 2% Dextrose).
All the data were from experiment-matched survival curves from
at least 40 cells assayed in each case.
(JPG)
S8 Figure Steady-state Tat2p-TAP levels in mutants with small
birth size. Tat2p levels in exponentially proliferating cells expressing
from its chromosomal location TAP-tagged Tat2p and lacking the
indicated genes were evaluated by SDS-PAGE and immunoblot-
ting. From the same samples, steady-state levels of untagged Cdk,
detected with an anti-PSTAIR antibody, are shown for comparison.
Overall loading is also shown from the Ponceau-stained blot.
(JPG)
S9 Figure Interfering with the expression of putative amino acid
transporters extends the lifespan of C. elegans. Survival curves for
animals fed with bacteria carrying an RNAi vector against C50D2.2
(A) or F23F1.6 (B) compared to control animals fed with bacteria
carrying the empty vector.Mean lifespans are shown in parentheses,
along with the number of animals assayed. The p value shown
associated with each experiment was calculated as in S1 Table.
(JPG)
S1 Dataset Genome-wide dataset of cell cycle parameters in
long-lived (LL) and not-long-lived (NLL) deletion strains lacking
non-essential genes (spreadsheet ‘‘Variables’’) and the associated
statistical correlations (spreadsheet ‘‘Statistics’’). The LL ORFs
were listed in SGD at the time of preparing this manuscript that
when deleted in the S288c strain background increased RLS. All
the non-essential deletion mutants we included in this analysis
were from the dataset in [49]. Among these, there were 137
deletion mutants in the S288c strain background classified as long-
lived in replicative lifespan assays (see S1 Table). The remaining
3,842 mutants of the dataset in [49] were not long-lived (NLL).
(XLSX)
S1 Table Summary of C. elegans lifespans.
(DOCX)
S2 Table Summary of D. melanogaster lifespans.
(DOCX)
S3 Table Intracellular amino acid levels upon ibuprofen
treatment.
(DOCX)
S4 Table Cell cycle parameters from synchronous cultures of LL
and NLL homozygous diploid deletion strains.
(DOCX)
S5 Table Intracellular amino acid levels in hxk2D and sch9D
cells.
(DOCX)
S6 Table S. cerevisiae strains used in this study.
(DOCX)
S7 Table Primer pairs for quantitative real-time PCR.
(DOCX)
Acknowledgments
We thank Jinny Johnson and Larry Dangott of the Texas A&M Protein
Chemistry Lab, for their help with amino acid analysis. We thank Vytas
Bankaitis (Texas A&M University) for comments on the manuscript. We
also thank J.P. Pellois (Texas A&M University), Mark McCormick and
other members of the Kennedy lab (The Buck Institute) who assisted in
technical aspects of the study.
Author Contributions
Conceived and designed the experiments: BKK MP. Performed the
experiments: CH SKT QTN ENP SRT SS BP ARF MVS RT MT MP.
Analyzed the data: CH SKT ENP MK AAM BKK MP. Contributed
reagents/materials/analysis tools: MK AAM BKK MP. Wrote the paper:
CH ENP MK AAM BKK MP.
Ibuprofen Extends Lifespan
PLOS Genetics | www.plosgenetics.org 14 December 2014 | Volume 10 | Issue 12 | e1004860
References
1. Niccoli T, Partridge L (2012) Ageing as a risk factor for disease. Curr Biol 22:
R741–752.
2. Kennedy BK, Pennypacker JK (2014) Drugs that modulate aging: the promising
yet difficult path ahead. Transl Res 163: 456–465.
3. Lucanic M, Lithgow GJ, Alavez S (2013) Pharmacological lifespan extension of
invertebrates. Ageing Res Rev 12: 445–458.
4. McCormick MA, Kennedy BK (2012) Genome-scale studies of aging: challenges
and opportunities. Curr Genomics 13: 500–507.
5. Johnson SC, Rabinovitch PS, Kaeberlein M (2013) mTOR is a key modulator of
ageing and age-related disease. Nature 493: 338–345.
6. McCormick MA, Tsai SY, Kennedy BK (2011) TOR and ageing: a complex
pathway for a complex process. Philos Trans R Soc Lond B Biol Sci 366: 17–
27.
7. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, et al.
(2013) Metformin improves healthspan and lifespan in mice. Nat Commun 4:
2192.
8. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R (2012) Are sirtuins
viable targets for improving healthspan and lifespan? Nat Rev Drug Discov 11:
443–461.
9. Hubbard BP, Sinclair DA (2014) Small molecule SIRT1 activators for the
treatment of aging and age-related diseases. Trends Pharmacol Sci 35: 146–154.
10. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The
hallmarks of aging. Cell 153: 1194–1217.
11. Wasko BM, Kaeberlein M (2014) Yeast replicative aging: a paradigm for
defining conserved longevity interventions. FEMS Yeast Research 14: 148–159.
12. Longo VD, Shadel GS, Kaeberlein M, Kennedy B (2012) Replicative and
Chronological Aging in Saccharomyces cerevisiae. Cell Metab 16: 18–31.
13. Steffen KK, Kennedy BK, Kaeberlein M (2009) Measuring Replicative Life
Span in the Budding Yeast. J Vis Exp: e1209.
14. Steinkraus KA, Kaeberlein M, Kennedy BK (2008) Replicative aging in yeast:
the means to the end. Annu Rev Cell Dev Biol 24: 29–54.
15. Smith ED, Tsuchiya M, Fox LA, Dang N, Hu D, et al. (2008) Quantitative
evidence for conserved longevity pathways between divergent eukaryotic species.
Genome Res 18: 564–570.
16. Furey SA, Waksman JA, Dash BH (1992) Nonprescription ibuprofen: side effect
profile. Pharmacotherapy 12: 403–407.
17. Kellstein DE, Waksman JA, Furey SA, Binstok G, Cooper SA (1999) The safety
profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis. J Clin
Pharmacol 39: 520–532.
18. DeArmond B, Francisco CA, Lin JS, Huang FY, Halladay S, et al. (1995) Safety
profile of over-the-counter naproxen sodium. Clin Ther 17: 587–601; discussion
586.
19. Rainsford KD, Roberts SC, Brown S (1997) Ibuprofen and paracetamol: relative
safety in non-prescription dosages. J Pharm Pharmacol 49: 345–376.
20. Rome LH, Lands WE (1975) Structural requirements for time-dependent
inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl
Acad Sci U S A 72: 4863–4865.
21. Vlad SC, Miller DR, Kowall NW, Felson DT (2008) Protective effects of
NSAIDs on the development of Alzheimer disease. Neurology 70: 1672–1677.
22. Gao X, Chen H, Schwarzschild MA, Ascherio A (2011) Use of ibuprofen and
risk of Parkinson disease. Neurology 76: 863–869.
23. McSharry C (2011) Parkinson disease: Could over-the-counter treatment protect
against Parkinson disease? Nat Rev Neurol 7: 244.
24. Cavalier-Smith T (2010) Kingdoms Protozoa and Chromista and the eozoan
root of the eukaryotic tree. Biol Lett 6: 342–345.
25. Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase isozymes: the biology
of prostaglandin synthesis and inhibition. Pharmacol Rev 56: 387–437.
26. Morita M, Osoda K, Yamazaki M, Shirai F, Matsuoka N, et al. (2009) Effects of
non-steroidal anti-inflammatory drugs on Abeta deposition in Abeta(1-42)
transgenic C. elegans. Brain Res 1295: 186–191.
27. Tootle TL, Spradling AC (2008) Drosophila Pxt: a cyclooxygenase-like
facilitator of follicle maturation. Development 135: 839–847.
28. Varvas K, Kurg R, Hansen K, Jarving R, Jarving I, et al. (2009) Direct evidence
of the cyclooxygenase pathway of prostaglandin synthesis in arthropods: genetic
and biochemical characterization of two crustacean cyclooxygenases. Insect
Biochem Mol Biol 39: 851–860.
29. Pages M, Rosello J, Casas J, Gelpi E, Gualde N, et al. (1986) Cyclooxygenase
and lipoxygenase-like activity in Drosophila melanogaster. Prostaglandins 32:
729–740.
30. Tucker CL, Fields S (2004) Quantitative genome-wide analysis of yeast deletion
strain sensitivities to oxidative and chemical stress. Comp Funct Genomics 5:
216–224.
31. Schmidt A, Hall MN, Koller A (1994) Two FK506 resistance-conferring genes
in Saccharomyces cerevisiae, TAT1 and TAT2, encode amino acid permeases
mediating tyrosine and tryptophan uptake. Mol Cell Biol 14: 6597–6606.
32. Ljungdahl PO, Daignan-Fornier B (2012) Regulation of amino acid, nucleotide,
and phosphate metabolism in Saccharomyces cerevisiae. Genetics 190: 885–929.
33. Regenberg B, During-Olsen L, Kielland-Brandt MC, Holmberg S (1999)
Substrate specificity and gene expression of the amino-acid permeases in
Saccharomyces cerevisiae. Curr Genet 36: 317–328.
34. Heitman J, Koller A, Kunz J, Henriquez R, Schmidt A, et al. (1993) The
immunosuppressant FK506 inhibits amino acid import in Saccharomyces
cerevisiae. Mol Cell Biol 13: 5010–5019.
35. Loewith R, Hall MN (2011) Target of rapamycin (TOR) in nutrient signaling
and growth control. Genetics 189: 1177–1201.
36. Beck T, Schmidt A, Hall MN (1999) Starvation induces vacuolar targeting and
degradation of the tryptophan permease in yeast. J Cell Biol 146: 1227–1238.
37. Schmidt A, Beck T, Koller A, Kunz J, Hall MN (1998) The TOR nutrient
signalling pathway phosphorylates NPR1 and inhibits turnover of the
tryptophan permease. EMBO J 17: 6924–6931.
38. Ghaemmaghami S, Huh WK, Bower K, Howson RW, Belle A, et al. (2003)
Global analysis of protein expression in yeast. Nature 425: 737–741.
39. Belle A, Tanay A, Bitincka L, Shamir R, O’Shea EK (2006) Quantification of
protein half-lives in the budding yeast proteome. Proc Natl Acad Sci U S A 103:
13004–13009.
40. Mousley CJ, Yuan P, Gaur NA, Trettin KD, Nile AH, et al. (2012) A sterol-
binding protein integrates endosomal lipid metabolism with TOR signaling and
nitrogen sensing. Cell 148: 702–715.
41. Valenzuela L, Aranda C, Gonzalez A (2001) TOR modulates GCN4-dependent
expression of genes turned on by nitrogen limitation. J Bacteriol 183: 2331–
2334.
42. Cherkasova VA, Hinnebusch AG (2003) Translational control by TOR and
TAP42 through dephosphorylation of eIF2alpha kinase GCN2. Genes Dev 17:
859–872.
43. Hinnebusch AG (1985) A hierarchy of trans-acting factors modulates translation
of an activator of amino acid biosynthetic genes in Saccharomyces cerevisiae.
Mol Cell Biol 5: 2349–2360.
44. Crespo JL, Helliwell SB, Wiederkehr C, Demougin P, Fowler B, et al. (2004)
NPR1 kinase and RSP5-BUL1/2 ubiquitin ligase control GLN3-dependent
transcription in Saccharomyces cerevisiae. J Biol Chem 279: 37512–37517.
45. Tate JJ, Cooper TG (2013) Five conditions commonly used to down-regulate tor
complex 1 generate different physiological situations exhibiting distinct
requirements and outcomes. J Biol Chem 288: 27243–27262.
46. Kaeberlein M, Powers RW, 3rd, Steffen KK, Westman EA, Hu D, et al. (2005)
Regulation of yeast replicative life span by TOR and Sch9 in response to
nutrients. Science 310: 1193–1196.
47. Howell AS, Lew DJ (2012) Morphogenesis and the cell cycle. Genetics 190: 51–
77.
48. Hoose SA, Rawlings JA, Kelly MM, Leitch MC, Ababneh QO, et al. (2012) A
systematic analysis of cell cycle regulators in yeast reveals that most factors act
independently of cell size to control initiation of division. PLoS Genet 8:
e1002590.
49. Truong SK, McCormick RF, Polymenis M (2013) Genetic Determinants of Cell
Size at Birth and Their Impact on Cell Cycle Progression in Saccharomyces
cerevisiae. G3 (Bethesda) 3: 1525–1530.
50. Giaever G, Chu AM, Ni L, Connelly C, Riles L, et al. (2002) Functional
profiling of the Saccharomyces cerevisiae genome. Nature 418: 387–391.
51. Jorgensen P, Nishikawa JL, Breitkreutz BJ, Tyers M (2002) Systematic
identification of pathways that couple cell growth and division in yeast. Science
297: 395–400.
52. Di Talia S, Skotheim JM, Bean JM, Siggia ED, Cross FR (2007) The effects of
molecular noise and size control on variability in the budding yeast cell cycle.
Nature 448: 947–951.
53. Turner JJ, Ewald JC, Skotheim JM (2012) Cell size control in yeast. Curr Biol
22: R350–359.
54. Strong R, Miller RA, Astle CM, Floyd RA, Flurkey K, et al. (2008)
Nordihydroguaiaretic acid and aspirin increase lifespan of genetically hetero-
geneous male mice. Aging Cell 7: 641–650.
55. Ching TT, Chiang WC, Chen CS, Hsu AL (2011) Celecoxib extends C. elegans
lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity.
Aging Cell 10: 506–519.
56. Janssen GM, Venema JF (1985) Ibuprofen: plasma concentrations in man. J Int
Med Res 13: 68–73.
57. Mehlisch DR, Sykes J (2013) Ibuprofen blood plasma levels and onset of
analgesia. Int J Clin Pract Suppl: 3–8.
58. Braus GH (1991) Aromatic amino acid biosynthesis in the yeast Saccharomyces
cerevisiae: a model system for the regulation of a eukaryotic biosynthetic
pathway. Microbiol Rev 55: 349–370.
59. De Marte ML, Enesco HE (1986) Influence of low tryptophan diet on survival
and organ growth in mice. Mech Ageing Dev 36: 161–171.
60. Oxenkrug GF, Navrotskaya V, Voroboyva L, Summergrad P (2011) Extension
of life span of Drosophila melanogaster by the inhibitors of tryptophan-
kynurenine metabolism. Fly (Austin) 5: 307–309.
61. van der Goot AT, Nollen EA (2013) Tryptophan metabolism: entering the field
of aging and age-related pathologies. Trends Mol Med 19: 336–344.
62. Stone TW, Stoy N, Darlington LG (2013) An expanding range of targets for
kynurenine metabolites of tryptophan. Trends Pharmacol Sci 34: 136–143.
63. Braidy N, Guillemin GJ, Grant R (2011) Effects of Kynurenine Pathway
Inhibition on NADMetabolism and Cell Viability in Human Primary Astrocytes
and Neurons. Int J Tryptophan Res 4: 29–37.
64. Heitman J, Movva NR, Hall MN (1991) Targets for cell cycle arrest by the
immunosuppressant rapamycin in yeast. Science 253: 905–909.
Ibuprofen Extends Lifespan
PLOS Genetics | www.plosgenetics.org 15 December 2014 | Volume 10 | Issue 12 | e1004860
65. Hartwell LH, Unger MW (1977) Unequal division in Saccharomyces cerevisiae
and its implications for the control of cell division. J Cell Biol 75: 422–435.
66. Johnston GC, Pringle JR, Hartwell LH (1977) Coordination of growth with cell
division in the yeast Saccharomyces cerevisiae. Exp Cell Res 105: 79–98.
67. Bilinski T, Zadrag-Tecza R, Bartosz G (2012) Hypertrophy hypothesis as an
alternative explanation of the phenomenon of replicative aging of yeast. FEMS
Yeast Res 12: 97–101.
68. Zadrag R, Kwolek-Mirek M, Bartosz G, Bilinski T (2006) Relationship between
the replicative age and cell volume in Saccharomyces cerevisiae. Acta
Biochimica Polonica 53: 747–751.
69. Yang J, Dungrawala H, Hua H, Manukyan A, Abraham L, et al. (2011) Cell size
and growth rate are major determinants of replicative lifespan. Cell Cycle 10:
144–155.
70. Kaeberlein M (2012) Hypertrophy and senescence factors in yeast aging. A reply
to Bilinski et al. FEMS Yeast Res 12: 269–270.
71. Ganley AR, Breitenbach M, Kennedy BK, Kobayashi T (2012) Yeast
hypertrophy: cause or consequence of aging? Reply to Bilinski et al. FEMS
Yeast Res 12: 267–268.
72. Delaney JR, Sutphin GL, Dulken B, Sim S, Kim JR, et al. (2011) Sir2 deletion
prevents lifespan extension in 32 long-lived mutants. Aging Cell 10: 1089–1091.
73. Delaney JR, Murakami CJ, Olsen B, Kennedy BK, Kaeberlein M (2011)
Quantitative evidence for early life fitness defects from 32 longevity-associated
alleles in yeast. Cell Cycle 10: 156–165.
74. Gems D, Partridge L (2008) Stress-response hormesis and aging: "that which
does not kill us makes us stronger". Cell Metab 7: 200–203.
75. Kaiser C, Michaelis S, Mitchell A, Cold Spring Harbor Laboratory. (1994)
Methods in yeast genetics: a Cold Spring Harbor Laboratory course manual.
Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. vii, 234 p. p.
76. Heinrikson RL, Meredith SC (1984) Amino acid analysis by reverse-phase high-
performance liquid chromatography: precolumn derivatization with phenyli-
sothiocyanate. Anal Biochem 136: 65–74.
77. Kushnirov VV (2000) Rapid and reliable protein extraction from yeast. Yeast
16: 857–860.
78. Sutphin GL, Kaeberlein M (2009) Measuring Caenorhabditis elegans Life Span
on Solid Media. J Vis Exp: e1152.
79. Brejning J, Norgaard S, Scholer L, Morthorst TH, Jakobsen H, et al. (2014) Loss
of NDG-4 extends lifespan and stress resistance in Caenorhabditis elegans.
Aging Cell 13: 156–164.
80. Ashburner M (1989) Drosophila. A laboratory handbook.: Cold Spring Harbor,
N.Y.: Cold Spring Harbor Laboratory, 1989. 1331 p.
81. Wang C, Li Q, Redden D, Weindruch R, Allison D (2004) Statistical methods
for testing effects on "maximum lifespan". Mech Ageing Dev 125: 629–632.
Ibuprofen Extends Lifespan
PLOS Genetics | www.plosgenetics.org 16 December 2014 | Volume 10 | Issue 12 | e1004860
